Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer

Inclusion Criteria:

* Informed consent form
* Histologically confirmed locally advanced (stages III and IVb), squamous cell carcinoma of the oropharynx and hypopharynx
* The tumor mass had to be measurable
* Karnofsky performance status ≥70
* Life expectancy estimated than 6 months
* Hematologic: WBC≥4×109 /L , plateletes≥100×109 /L, haemoglobin ≥100 g/L；
* Hepatic: AST/ALT\<1.5 times upper limit of normal (ULN)；serum bilirubin\<1.5 times ULN;
* Renal: Creatinine\<1.5 times ULN；

Exclusion Criteria:

* Known distant metastases
* Primary tumor and nodes received surgery(except of biopsy)
* Received other anti EGFR monoclonal antibody treatment
* Previous chemotherapy or radiotherapy
* Participation in other interventional clinical trials within 1 month
* Other malignant tumor (except of non-melanoma skin Cancer or carcinoma in situ of cervix)
* History of serious allergic or allergy
* History of Serious lung or heart disease
* Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant